The tamoxifen-associated risk of any other cancers was nonsignificant.
The IBIS-I trial was supported by Cancer Research UK. Dr. Cuzick has received funding for other trials from AstraZeneca and is a consultant for AstraZeneca. The company also provided both the study drug and placebo.
On Twitter @alz_gal